Following his session at #AACR26, Brian Ruffell, PhD, highlights the role of ENPP1 in BRCA1-deficient breast cancer.

His research shows these tumors overexpress ENPP1, which can suppress immune detection. Targeting the enzyme with antibodies developed in the lab may restore immune recognition and offer a promising strategy for treating breast cancers with homologous recombination deficiency. #MoffittAACR26 @AACR